PNAS:研究发现利尿剂新的治疗基因靶标
2012-08-01 范振光 生物谷
近日,辛辛那提大学(UC)研究人员已经确定了利尿剂治疗那些如充血性心脏衰竭、肝硬化或肾功能衰竭患者新的治疗靶标。 这些结果发表在7月30日的PNAS期刊上,这可能会导致25年来第一个新的利尿剂治疗可以帮助利尿剂抵抗的患者。 Manoocher Soleimani医师说利尿剂的作用是增加尿量帮助患者处理自己多余的液体,因为他们的肾脏是无法做到的。在过去的几十年中,医生已使用
Double knockout of pendrin and Na-Cl cotransporter (NCC) causes severe salt wasting, volume depletion, and renal failure
Manoocher Soleimania,Sharon Baronea,b,c, Jie Xua,b,c, Gary E. Shulld, Faraz Siddiquib, Kamyar Zahedia,b,c, and Hassane Amlalb,c
The Na-Cl cotransporter (NCC), which is the target of inhibition by thiazides, is located in close proximity to the chloride-absorbing transporter pendrin in the kidney distal nephron. Single deletion of pendrin or NCC does not cause salt wasting or excessive diuresis under basal conditions, raising the possibility that these transporters are predominantly active during salt depletion or in response to excess aldosterone. We hypothesized that pendrin and NCC compensate for loss of function of the other under basal conditions, thereby masking the role that each plays in salt absorption. To test our hypothesis, we generated pendrin/NCC double knockout (KO) mice by crossing pendrin KO mice with NCC KO mice. Pendrin/NCC double KO mice displayed severe salt wasting and sharp increase in urine output under basal conditions. As a result, animals developed profound volume depletion, renal failure, and metabolic alkalosis without hypokalemia, which were all corrected with salt replacement. We propose that the combined inhibition of pendrin and NCC can provide a strong diuretic regimen without causing hypokalemia for patients with fluid overload, including patients with congestive heart failure, nephrotic syndrome, diuretic resistance, or generalized edema.
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#研究发现#
52
#PNAS#
58
#利尿剂#
67
#靶标#
59